medigraphic.com
ISSN 1561-2988 (Impreso)

2014, Número 3

<< Anterior Siguiente >>

Rev Cubana Farm 2014; 48 (3)


Patogenia y tratamientos actuales de la enfermedad de Alzheimer

Albert CMJ, Martínez PR, Gutiérrez RA, Hakim RD, Pérez DG

Idioma: Español
Referencias bibliográficas: 41
Paginas: 508-518
Archivo PDF: 132.73 Kb.


RESUMEN

El Alzheimer es una enfermedad neurodegenerativa que se manifiesta como deterioro cognitivo y trastornos conductuales. En Cuba, junto a la demencia, ocupa el lugar número 6 en el cuadro de principales causas de muerte. No hay tratamiento eficaz para detener la progresión del Alzheimer. Sin embargo, algunas terapias detienen o ralentizan temporalmente el deterioro cognitivo, funcional y conductual de la enfermedad. En el trabajo se presenta una revisión actualizada a partir de la base de datos MEDLINE (2008-2013) sobre los mecanismos patológicos y los medicamentos usados en el tratamiento de los pacientes con la referida afección.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sun X, Jin L, Ling P. Review of drugs for Alzheimer's disease. Drug Discov Ther. 2012;6(6):285-90.

  2. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain. 2011;4:3-15.

  3. Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol. 2010;8:69-80.

  4. DeFina P, Scolaro R, Glenn M, Lichtenstein J, Fellus J. Alzheimer's Disease Clinical and Research Update for Health Care Practitioners. J Aging Res. 2013;2:10-9.

  5. Lezak MD. Neuropsychological Assessment. 5th ed. New York: Oxford University Press; 2012.

  6. Jack CJr, Albert MS, Knopman DS. Introduction to the recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7(3):257-62.

  7. Anuario Estadistico de Salud 2011. Dirección Nacional de Registros Médicos y Estadísticas de Salud. La Habana: Ministerio de Salud Pública; 2012.

  8. Llibre JJ. Aging and Dementia: Implications for Cuba's Research Community, Public Health and Society. MEDICC Rev. 2013;(4):54-9.

  9. Bondi MW, Salmon DP, Kaszniak AW. The neuropsychology of dementia. Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders. New York: Oxford University Press; 2009.

  10. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 2010;120:385-99.

  11. Wollen KA. Alzheimer's disease: The pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev. 2010;15:223-44.

  12. Pagani L, Eckert A. Amyloid-β interaction with mitochondria. Int J Alzheimers Dis. 2011;10:1-11.

  13. Itkin A, Dupres B, Dufrene YF, Bechinger B, Ruysschaert JM, Raussens V. Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One. 2011;6:1-10.

  14. Armstrong RA. The pathogenesis of Alzheimer's disease: A reevaluation of the "amyloid cascade hypothesis". Int J Alzheimers Dis. 2011;10:1-6.

  15. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brainbarrier model. J Biol Chem. 2011;286:17536-42.

  16. Kawahara M, Kato-Negishi M. Link between aluminium and the pathogenesis of Alzheimer's disease: The integration of the aluminium and amyloid cascade hypotheses. Int J Alzheimers Dis. 2011;10:1-17.

  17. Mutter J, Curth A, Naumann J, Deth R, Walach H. Does inorganic mercury play a role in Alzheimer's disease? A systematic review and an integrated molecular mechanism. J Alzheimers Dis. 2010;22:357-74.

  18. Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(4):61-71.

  19. McKhann GM, Knopman DS, Chertkow H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7(3):263-9.

  20. Warren JD, Fletcher PD, Golden HL. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol. 2012;8(8):451-64.

  21. Achterberg W, Pieper MJ, van Dalen-Kok AH, de Waal MW, Husebo BS, Lautenbacher S, et al. Pain management in patients with dementia. Clin Interv Aging. 2013;8:1471-82.

  22. Mitrushina M. Cognitive screening methods. In: Grant I, Adams K, editors. Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders. New York: Oxford University Press; 2009. p. 101-26.

  23. Association As. Alzheimer's disease facts and figures. Alzheimer's Dement. 2012 [cited 2013 Nov 12];8(2). Available from: http://www.alz.org/downloads/facts_figures_2012.pdf

  24. CDC. Alzheimer's disease. 2010 [cited 2013 Nov 12]. Available from: http://www.cdc.gov/Features/Alzheimers/index.html

  25. Malamut BL, Ryan LM. Dementia: behavioral and cognitive aspects. In: Sirven JI, Malamut BL, editors. Clinical Neurology of the Older Adults. 2nd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008. p. 318-38.

  26. O'Bryant SE, Lacritz LH, Hall J. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol. 2010;67(6):746-9.

  27. Herrmann N, Chau SA, Kircanski U, Lanctˆot KL. Current and emerging drug treatment options for Alzheimers disease: a systematic review. Drugs. 2011;71(15):2031-65.

  28. Corbett A, Williams G, Ballard C. Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer's Disease. Pharmaceuticals (Basel). 2013;6(10):1304-21.

  29. Howard R, McShane R, Lindesay J. Donepezil and memantine for moderate-tosevere Alzheimer's disease. New Engl J Med.2012;66(10):893-903.

  30. Molino I, Colucci L, Fasanaro AM, Traini E, Amenta F. Effic acy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials. Scientific World Journal. 2013;2013:925702.

  31. Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J. Reviews: Effects of transdermal rivastigmine on ADAScog items in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010;25:627-33.

  32. Zheng R, Su YF. Research progress of clinical use of Huperzine A. Pract Pharm Clin Remedies. 2008;11:107-8.

  33. Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. Clin Interv Aging. 2010;5:1-6.

  34. Jakubik J, Michal P, Machova E, Dolezal V. Importance and prospects for design of selective muscarinic agonists. Physiol Res. 2008;7(Suppl 3):39-47.

  35. Saulle R, Semyonov L, La Torre G. Cost and cost-effectiveness of the Mediterranean diet: results of a systematic review. Nutrients. 2013;5(11):4566-86.

  36. Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol. 2010;8:228-42.

  37. Krause DL, Muller N. Neuroinflammation, microglia and implications for antiinflammatory treatment in Alzheimer's disease. Int J Alzheimers Dis. 2010;10:1-9.

  38. Oshiro S, Morioka MS, Kikuchi M. Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci. 2011;10:1155-63.

  39. Boutajangout A, Wisniewski T. The Innate Immune System in Alzheimer's Disease. Int J Cell Biol. 2013;2013:5763-83.

  40. Xing XN, Zhang WG, Sha S, Li Y, Guo R, Wang C, et al. Amyloid β 3-10 DNA vaccination suggests a potential new treatment for Alzheimer's disease in BALB/c mice. Chin Med J (Engl). 2011;124:2636-41.

  41. Voss MW, Erickson KI, Prakash RS. Neurobiological markers of exercise-related brain plasticity in older adults. Brain Behav Immun. 2013;28:90-9.




2020     |     www.medigraphic.com